## CORRECTION

## **Open Access**

# Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma



Thomas Powles<sup>1\*</sup>, Toni K. Choueiri<sup>2</sup>, Robert J. Motzer<sup>3</sup>, Eric Jonasch<sup>4</sup>, Sumanta Pal<sup>5</sup>, Nizar M. Tannir<sup>4</sup>, Sabina Signoretti<sup>6</sup>, Rajesh Kaldate<sup>7</sup>, Christian Scheffold<sup>7</sup>, Evelyn Wang<sup>7</sup>, Dana T. Aftab<sup>7</sup>, Bernard Escudier<sup>8</sup> and Daniel J. George<sup>9</sup>

### Correction to: BMC Cancer 21, 904 (2021) https://doi.org/10.1186/s12885-021-08630-w

Following publication of the original article [1], it was noticed that uncorrected page proofs were mistakenly published. The publishers apologise for this error. The original article [1] has been corrected.

Below is a table of corrections which have been implemented in the original article.

Section	Originally published text	Corrected text
Article note	Rajesh Kaldate <sup>7</sup> & Evelyn Wang <sup>7</sup>	Rajesh Kaldate <sup>7†</sup> & Evelyn Wang <sup>7†</sup> <sup>†</sup> Affiliation at the time of the study.
Abstract	Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013).	Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). https:// clinicaltrials.gov/ct2/show/ NCT01865747
Table 1 note	Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of for IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively	Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Figure 1	Footnote is missing	High levels and low levels are defined by ≥median and < median, respectively. NR, not reached.
Row 2	1.32 (0.95–1.83)	1.32 (0.95, 1.83)
Row 6	ΔIL8	ΔIL-8
Table 6 Row 11	IL8	IL-8

\* Correspondence: thomas.powles1@nhs.net †Rajesh Kaldate and Evelyn Wang's affiliation at the time of the study. <sup>1</sup>Barts Cancer Institute, Queen Mary University of London, London, UK Full list of author information is available at the end of the article

The original article can be found online at https://doi.org/10.1186/s12885-



021-08630-w

© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wish http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued)

Table 6 Row 12	0.97 (0.87–1.07)	0.97 (0.87, 1.07)	
Table 6 Row 16	<b>Δ</b> IL8	<b>Δ</b> IL-8	
Table 6 Row 18	IL8	IL-8	
Table 6 Row 21	IL8 / 1.35 (0.95–1.9)	IL-8 / 1.35 (0.95, 1.9)	

Table 6 note Biomarkers were included Biomarkers were included in the multivariable analysis in the multivariable analysis if p < 0.10 in the univariate if p < 0.10 in the univariate analyses. Hazard ratios are analyses. Hazard ratios are for high versus low for high versus low biomarker levels.  $\Delta$ biomarker levels. Indicates the covariate is  $\Delta$  indicates the covariate is change in the biomarker at change in the biomarker at week 4; all other covariates week 4: all other covariates are baseline biomarkers are baseline biomarkers dichotomized at the dichotomized at the median \* p < 0.05 for the median \* p < 0.05 for the analysis analysis Competing Dr. Powles has received Dr. Powles has received interests honoraria from Astellas honoraria from Astellas Pharma, AstraZeneca, Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck. Johnson & Johnson, Merck, Merck, Merck Serono, MSD, Merck Serono, MSD, Novar-Novartis, Pfizer, Roche, and tis, Pfizer, Roche, and Se-Seattle Genetics; has a conattle Genetics; has a sulting or advisory role consulting or advisory role with Astellas Pharma, Astrawith Astellas Pharma, Astra-Zeneca, Bristol-Myers Zeneca, Bristol-Myers Squibb, Eisai, Exelixis, Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Incyte, Ipsen, Johnson & Johnson, Merck, Merck Ser-Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, ono, MSD, Novartis, Pfizer, Roche, and Seattle Genet-Roche, and Seattle Genetics: has received research ics: has received research funding from Astellas funding from Astellas Pharma, AstraZeneca, Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Ser-Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, ono, MSD, Novartis, Pfizer, Roche, and Seattle Genet-Roche, and Seattle Genetics; and has received travel/ ics; and has received travel/ accommodation/other exaccommodation/other expenses from AstraZeneca, penses from AstraZeneca, Ipsen, MSD, Pfizer, and Ipsen, MSD, Pfizer, and Roche. Roche.

Competing interests	Dr. Wang is employed by Exelixis; and has stock/ ownership interests with Exelixis.	Dr. Wang is a former employee of Exelixis; has stock/ownership interests with Exelixis.
Additional file 1	'Track changed' version was published	Clean version is published this correction article and the original article has been udpated

#### **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-08693-9.

Additional	file	1.
Additional		••

#### Author details

<sup>1</sup>Barts Cancer Institute, Queen Mary University of London, London, UK. <sup>2</sup>Dana-Farber Cancer Center, Boston, MA, USA. <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA. <sup>4</sup>University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>5</sup>City of Hope National Medical Center, Duarte, CA, USA. <sup>6</sup>Brigham and Women's Hospital, Boston, MA, USA. <sup>7</sup>Exelixis, Inc, Alameda, CA, USA. <sup>8</sup>Gustave-Roussy, Villejuif, France. <sup>9</sup>Duke Cancer Institute, Durham, NC, USA.

#### Published online: 15 September 2021

#### Reference

 Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021;21(1):904. https://doi.org/10.1186/s12885-021-08630-w.